| MeSH term | MeSH ID | Detail |
|---|---|---|
| Inflammatory Bowel Diseases | D015212 | 9 associated lipids |
| Reperfusion Injury | D015427 | 65 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Fatty Liver | D005234 | 48 associated lipids |
| Cataract | D002386 | 34 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Jusko WJ and D'Ambrosio R | Monitoring FK 506 concentrations in plasma and whole blood. | 1991 | Transplant. Proc. | pmid:1721260 |
| Venkataramanan R et al. | Pharmacokinetics of FK 506 in transplant patients. | 1991 | Transplant. Proc. | pmid:1721261 |
| Christians U et al. | High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. | 1991 | Transplant. Proc. | pmid:1721262 |
| Beysens AJ et al. | FK 506: monitoring in plasma or in whole blood? | 1991 | Transplant. Proc. | pmid:1721263 |
| Grenier FC et al. | A whole blood FK 506 assay for the IMx analyzer. | 1991 | Transplant. Proc. | pmid:1721264 |
| Akselband Y et al. | Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. | 1991 | Transplant. Proc. | pmid:1721292 |
| Schreiber SL et al. | Immunophilin-ligand complexes as probes of intracellular signaling pathways. | 1991 | Transplant. Proc. | pmid:1721293 |
| Ullman KS et al. | Site of action of cyclosporine and FK 506 in the pathways of communication between the T-lymphocyte antigen receptor and the early activation genes. | 1991 | Transplant. Proc. | pmid:1721294 |
| Sigal NH et al. | Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506? | 1991 | Transplant. Proc. | pmid:1721295 |
| Motta I et al. | FK 506 favors the generation of memory T cells in vitro. | 1991 | Transplant. Proc. | pmid:1721324 |
| Nakata S et al. | Immunosuppressive effect of FK 506 on cytotoxic T lymphocytes and delayed-type hypersensitivity in rats. | 1991 | Transplant. Proc. | pmid:1721325 |
| Cooper MH et al. | Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. | 1991 | Transplant. Proc. | pmid:1721326 |
| Didlake R and Grogan J | Effect of FK 506 on rat leukocyte chemotaxis. | 1991 | Transplant. Proc. | pmid:1721327 |
| Hultsch T and Hohman RJ | Categorizing receptor-signaling pathways with FK 506 and rapamycin. | 1991 | Transplant. Proc. | pmid:1721328 |
| Whiteside TL et al. | Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721356 |
| Van Thiel DH et al. | Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. | 1991 | Transplant. Proc. | pmid:1721357 |
| Armitage JM et al. | The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721358 |
| Armitage JM et al. | The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721359 |
| Zeevi A et al. | Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. | 1991 | Transplant. Proc. | pmid:1703341 |
| van Hoek B et al. | Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. | 1991 | Transplant. Proc. | pmid:1703343 |
| McCauley J et al. | The question of FK 506 nephrotoxicity after liver transplantation. | 1991 | Transplant. Proc. | pmid:1703344 |
| Alessiani M et al. | Infections in adult liver transplant patients under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703345 |
| Winkler M et al. | Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. | 1991 | Transplant. Proc. | pmid:1721389 |
| Schmidt RJ et al. | Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721390 |
| Tze WJ et al. | Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. | 1991 | Transplant. Proc. | pmid:1721391 |
| Doi R et al. | Mechanisms by which FK 506 affects exocrine pancreas in rats. | 1991 | Transplant. Proc. | pmid:1721392 |
| Steinmann B et al. | Mechanism of action of FK 506 and cyclosporin. | 1991 | Lancet | pmid:1704088 |
| Langrehr JM et al. | Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. | 1991 | Transplant. Proc. | pmid:1721425 |
| Takeda Y et al. | Effect of FK 506 on the survival of rat small bowel allografts. | 1991 | Transplant. Proc. | pmid:1721426 |
| Fukuzawa M et al. | Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. | 1991 | Transplant. Proc. | pmid:1721427 |
| Ogasa N et al. | Effect of FK 506 on growth of transplanted newborn rat intestine. | 1991 | Transplant. Proc. | pmid:1721428 |
| de Bruin RW et al. | Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. | 1991 | Transplant. Proc. | pmid:1721429 |
| Metcalfe S and Milner J | Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. | 1991 | Transplantation | pmid:1710844 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Neuberger J | FK 506--a promise of good things to come? | 1991 | Hepatology | pmid:1711005 |
| Halloran PF and Madrenas J | The mechanism of action of cyclosporine: a perspective for the 90's. | 1991 | Clin. Biochem. | pmid:1711939 |
| Roat MI et al. | Treatment of Cogan's syndrome with FK 506: a case report. | 1991 | Transplant. Proc. | pmid:1721457 |
| Carroll PB et al. | The use of FK 506 in new-onset type I diabetes in man. | 1991 | Transplant. Proc. | pmid:1721458 |
| McCauley J et al. | FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. | 1991 | Transplant. Proc. | pmid:1721459 |
| Carrieri G et al. | Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. | 1991 | Transplant. Proc. | pmid:1721460 |
| Christians U et al. | Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. | 1991 | Clin. Biochem. | pmid:1714802 |
| Turka LA and Thompson CB | Structure-function relationship of immunosuppressive drugs: a cautionary tale. | 1991 | Hepatology | pmid:1714876 |
| Brizuela L et al. | Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. | 1991 | Mol. Cell. Biol. | pmid:1715022 |
| Heitman J et al. | Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. | 1991 | Science | pmid:1715094 |
| Morris RE | Rapamycin: FK506's fraternal twin or distant cousin? | 1991 | Immunol. Today | pmid:1715165 |
| Takaya S et al. | Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1703691 |
| Hildebrandt A et al. | FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. | 1991 | Transplant. Proc. | pmid:1703694 |
| Ericzon BG et al. | Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. | 1991 | Transplant. Proc. | pmid:1703695 |
| Kumano K et al. | FK 506-induced nephrotoxicity in rats. | 1991 | Transplant. Proc. | pmid:1703696 |
| Kuroki H et al. | Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. | 1991 | Transplant. Proc. | pmid:1703697 |